NCT05303038
Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting
Phase 2
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: Female
Age: 18 Years to 70 Years (Adult, Older Adult)
Location of Metastases: Liver
Additional Notes: 
Exclusions: Patients with brain metastases; Patients without more than 2 prior lines systemic therapy
https://ClinicalTrials.gov/show/NCT05303038